Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials-Reference-Cited by-同舟云学术

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

Published:2018-03 Issue:3 Volume:19 Page:416-426
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

D'Angelo Sandra P,Mahoney Michelle R,Van Tine Brian A,Atkins James,Milhem Mohammed M,Jahagirdar Balkrishna N,Antonescu Cristina R,Horvath Elise,Tap William D,Schwartz Gary K,Streicher Howard

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016

2. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial;Seddon;Lancet Oncol,2017

3. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial;Demetri;J Clin Oncol,2016

4. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial;Schöffski;Lancet,2016

5. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial;van der Graaf;Lancet,2012

Cited by 538 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA mismatch repair deficiency as a biomarker in sarcoma;Surgical Oncology Insight;2024-12

2. Molecular markers of proliferation, DNA repair, and immune infiltration defines high-risk subset of resectable retroperitoneal sarcomas;Surgical Oncology;2024-10

3. Advances on immunotherapy for osteosarcoma;Molecular Cancer;2024-09-09

4. Osteoimmunology in bone malignancies: A symphony with evil;Journal of the National Cancer Center;2024-09

5. A Self-Assembling Immune-Featured Osteosarcoma Patient/PDX Derived Organoid Model and Biobank for Personalized Immune Therapy;2024-08-11